America’s Obsession With Weight-Loss Drugs Is Affecting the Economy of Denmark

Ozempic and Wegovy are tilting the scales of Denmark’s economy.

Their Danish manufacturer, Novo Nordisk, has generated billions of dollars of revenue and supercharged the company’s market capitalisation. That has led to lower interest rates in the country, according to a bank report and economists.

The market value of Denmark’s biggest company has risen by more than a third so far this year to about $419 billion, bigger than the country’s gross domestic product of about $406 billion. The measures aren’t synonymous: market capitalisation is the value of all Novo Nordisk shares, while GDP measures goods and services produced in a year. But the comparison demonstrates how Novo Nordisk has surged past companies such as Lego and Carlsberg to sway the economy of its nordic homeland.

Take foreign-exchange management for one example.

Denmark’s currency, the krone, is pegged to the euro. Central bankers in Copenhagen adjust interest rates and make other interventions to keep its value steady with that of the continent’s common currency.

Novo Nordisk’s U.S. sales of Ozempic and Wegovy have been so strong that it has had to convert dollars into kroner in unusually large quantities, raising the krone’s value relative to the euro, said Danske Bank director Jens Naervig Pedersen.

“Because the pharmaceutical industry’s exports have grown so much, it’s creating a big influx of currency into the Danish economy,” he said.

Denmark’s central bankers have responded by keeping interest rates below the European Central Bank’s, weakening the krone, said Pedersen.

Denmark’s central bank declined to comment.

Novo Nordisk’s success with drugs used for weight loss and diabetes is overall a boon to the Danish economy, which will benefit from more jobs created by the company’s growth as it invests domestically, economists said. Lower interest rates also benefit home buyers who can secure mortgage rates somewhat lower than in the rest of Europe, they said.

“It is an embarrassment of riches—this is good for the Danish economy and they’re getting a lot of export revenues,” said Gian Maria Milesi-Ferretti, an economist and senior fellow at the Brookings Institution.

For small countries, having a domestic company play such a disproportionate role in the economy carries risks. For years, fellow Nordic nation Finland’s economy was dominated by telecom Nokia, which at its peak in 2000 accounted for 4% of the country’s GDP, more than a fifth of exports and some 70% of value on its stock exchange. It played a significant role in Finland’s growth from 1995-2007, when GDP per capita rose 55%, nearly double the increase in the U.S.

Nokia’s decline also coincided with a decade of economic stagnation in Finland after 2008. The collapse of Nokia’s handset market, largely because of competition from the iPhone that Apple introduced in 2007, exacerbated Finland’s economic woes, which under austerity policies and the eurozone crisis saw its per capita income decline over the next decade.

Novo Nordisk is now the second-most valuable public company in Europe after luxury brand LVMH Moët Hennessy Louis Vuitton.

Analysts estimate Novo Nordisk’s weight-loss drug sales to be $6.1 billion this year and to reach nearly $15 billion annually in 2027, according to data provider FactSet.

The boom in casual footware ushered in by the pandemic has ended, a potential problem for companies such as Adidas that benefited from the shift to less formal clothing, Bank of America says.

The casual footwear business has been on the ropes since mid-2023 as people began returning to office.

Analyst Thierry Cota wrote that while most downcycles have lasted one to two years over the past two decades or so, the current one is different.

It “shows no sign of abating” and there is “no turning point in sight,” he said.

Adidas and Nike alone account for almost 60% of revenue in the casual footwear industry, Cota estimated, so the sector’s slower growth could be especially painful for them as opposed to brands that have a stronger performance-shoe segment. Adidas may just have it worse than Nike.

Cota downgraded Adidas stock to Underperform from Buy on Tuesday and slashed his target for the stock price to €160 (about $187) from €213. He doesn’t have a rating for Nike stock.

Shares of Adidas listed on the German stock exchange fell 4.5% Tuesday to €162.25. Nike stock was down 1.2%.

Adidas didn’t immediately respond to a request for comment.

Cota sees trouble for Adidas both in the short and long term.

Adidas’ lifestyle segment, which includes the Gazelles and Sambas brands, has been one of the company’s fastest-growing business, but there are signs growth is waning.

Lifestyle sales increased at a 10% annual pace in Adidas’ third quarter, down from 13% in the second quarter.

The analyst now predicts Adidas’ organic sales will grow by a 5% annual rate starting in 2027, down from his prior forecast of 7.5%.

The slower revenue growth will likewise weigh on profitability, Cota said, predicting that margins on earnings before interest and taxes will decline back toward the company’s long-term average after several quarters of outperforming. That could result in a cut to earnings per share.

Adidas stock had a rough 2025. Shares shed 33% in the past 12 months, weighed down by investor concerns over how tariffs, slowing demand, and increased competition would affect revenue growth.

Nike stock fell 9% throughout the period, reflecting both the company’s struggles with demand and optimism over a turnaround plan CEO Elliott Hill rolled out in late 2024.

Investors’ confidence has faded following Nike’s December earnings report, which suggested that a sustained recovery is still several quarters away. Just how many remains anyone’s guess.

But if Adidas’ challenges continue, as Cota believes they will, it could open up some space for Nike to claw back any market share it lost to its rival.

Investors should keep in mind, however, that the field has grown increasingly crowded in the past five years. Upstarts such as On Holding and Hoka also present a formidable challenge to the sector’s legacy brands.

Shares of On and Deckers Outdoor , Hoka’s parent company, fell 11% and 48%, respectively, in 2025, but analysts are upbeat about both companies’ fundamentals as the new year begins.

The battle of the sneakers is just getting started.

America’s Obsession With Weight-Loss Drugs Is Affecting the Economy of Denmark

Novo Nordisk’s market capitalisation has matched the GDP of its home country

The pandemic-fuelled love affair with casual footwear is fading, with Bank of America warning the downturn shows no sign of easing.